About Caladrius

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases.

News

November 16, 2019
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

November 6, 2019
Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update

October 31, 2019
Caladrius Biosciences to Participate at Upcoming November Conferences

Events

November 6, 2019
Caladrius Biosciences 3rd Quarter 2019 Financial Results and Business Update Conference Call

September 10, 2019
21st Annual Global Investment Conference, Sponsored by H.C. Wainwright

August 8, 2019
Caladrius Biosciences 2nd Quarter 2019 Financial Results and Business Update Conference Call

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology